Researchers examine the potential utility of biomarkers of food intake on objective and accurate dietary assessments.
Roche’s Columvi receives marketing approval in Europe – Pharmaceutical Technology
Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to treat R/R DLBCL and is given for a fixed time, a maximum of 12 cycles.